{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Angiogenesis&page=9",
    "query": {
      "condition": "Angiogenesis",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 242,
    "total_pages": 25,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Angiogenesis&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Angiogenesis&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T02:09:06.416Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01251926",
      "title": "EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "EZN-2208",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 12,
      "start_date": "2010-11-15",
      "completion_date": "2014-04-23",
      "has_results": false,
      "last_update_posted_date": "2019-11-15",
      "last_synced_at": "2026-10-29T02:09:06.416Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01251926"
    },
    {
      "nct_id": "NCT03403686",
      "title": "Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "blood draw",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "98 Years",
        "sex": "ALL",
        "summary": "21 Years to 98 Years"
      },
      "enrollment_count": 104,
      "start_date": "2018-01-11",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-29T02:09:06.416Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03403686"
    },
    {
      "nct_id": "NCT00599105",
      "title": "Angiogenesis in Early Breast Cancer for Prognosis Prediction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Lesions"
      ],
      "interventions": [
        {
          "name": "magnetic resonance imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 90 Years · Female only"
      },
      "enrollment_count": 700,
      "start_date": "2000-11",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2010-11-19",
      "last_synced_at": "2026-10-29T02:09:06.416Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00599105"
    },
    {
      "nct_id": "NCT01009593",
      "title": "Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatocellular Carcinoma Non-resectable",
        "Hepatocellular Carcinoma Recurrent",
        "Carcinoma, Hepatocellular",
        "Liver Diseases",
        "Neoplasms by Histologic Type",
        "Digestive System Neoplasms",
        "Carcinoma",
        "Liver Neoplasms",
        "Neoplasms",
        "Neoplasms by Site",
        "Digestive System Diseases",
        "Adenocarcinoma",
        "Neoplasms, Glandular and Epithelial"
      ],
      "interventions": [
        {
          "name": "ABT-869",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1035,
      "start_date": "2010-01",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2012-09-10",
      "last_synced_at": "2026-10-29T02:09:06.416Z",
      "location_count": 13,
      "location_summary": "Beverly Hills, California • LaVerne, California • Orange, California + 8 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "LaVerne",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01009593"
    },
    {
      "nct_id": "NCT00586417",
      "title": "A Research Pilot Study in Healthy Volunteers to Evaluate Biomarkers for Novel Anticancer Treatments",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "punch biopsy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2007-01",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2013-12-03",
      "last_synced_at": "2026-10-29T02:09:06.416Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00586417"
    },
    {
      "nct_id": "NCT01134081",
      "title": "Expression of Angiogenic Biomarkers During Healing of Intra-Oral Soft Tissue Engineered Grafts",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gingival Recession"
      ],
      "interventions": [
        {
          "name": "CelTx™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Free Gingival Graft",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2008-01",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2017-08-21",
      "last_synced_at": "2026-10-29T02:09:06.416Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01134081"
    },
    {
      "nct_id": "NCT05859217",
      "title": "A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer",
        "NSCLC Stage IV",
        "Metastatic NSCLC - Non-Small Cell Lung Cancer",
        "Advanced NSCLC"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jun Zhang, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2024-12",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2024-05-08",
      "last_synced_at": "2026-10-29T02:09:06.416Z",
      "location_count": 4,
      "location_summary": "Kansas City, Kansas • Overland Park, Kansas • Kansas City, Missouri + 1 more",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Lee's Summit",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05859217"
    },
    {
      "nct_id": "NCT00117650",
      "title": "Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients With Intermittent Claudication",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Intermittent Claudication",
        "Peripheral Vascular Disease",
        "Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "Ad2/HIF-1α/VP16",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline (Placebo Control)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 289,
      "start_date": "2005-02",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2015-04-03",
      "last_synced_at": "2026-10-29T02:09:06.416Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Palo Alto, California • Sacramento, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00117650"
    },
    {
      "nct_id": "NCT01148407",
      "title": "Platelet Modulation: A Study of Angiogenic and Coagulation Proteins in Patients With Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Vermont",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2010-06",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2011-04-22",
      "last_synced_at": "2026-10-29T02:09:06.416Z",
      "location_count": 1,
      "location_summary": "Burlington, Vermont",
      "locations": [
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01148407"
    },
    {
      "nct_id": "NCT00083382",
      "title": "Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Pamidronate",
          "type": "DRUG"
        },
        {
          "name": "Thalidomide",
          "type": "DRUG"
        },
        {
          "name": "Zometa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "1998-12",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2015-06-24",
      "last_synced_at": "2026-10-29T02:09:06.416Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00083382"
    }
  ]
}